Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration

<div>A representative case showed remarkable PED reduction after switch from conbercept to ranibizumab. (a) OCT at baseline visit showed large PED with SRF. (b) 1 month after the third IVC, PED did not improve but progressed; SRF became hyperreflective on OCT. (c) Patient was then switched to IVR. One month after the first IVR, PED dramatically decreased with SRF partially resolved. (d) After 3 monthly injections of ranibizumab, no SRF was present on OCT and only a very shallow PED was left. The total follow-up was eight months.</div>

Journal of Ophthalmology

fig4

Figure 4

Figure 4: Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration 

Figure 4 | Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration 